Publicaciones en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (24)

2024

  1. Characterization of Chronic Graft-versus-host Disease After Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide: A Study on Behalf of GETH-TC

    Transplantation, Vol. 108, Núm. 10, pp. 2134-2143

  2. Real-World Experience with Isavuconazole in Allogeneic Stem Cell Transplantation in Spain

    Transplantation and Cellular Therapy, Vol. 30, Núm. 10, pp. 1033.e1-1033.e8

  3. Total body irradiation versus thiotepa/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia

    Bone Marrow Transplantation, Vol. 59, Núm. 8, pp. 1137-1145

2023

  1. LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors

    Frontiers in Immunology, Vol. 14

  2. Results of haploidentical transplant in patients with donor-specific antibodies: a survey on behalf of the Spanish Group of Hematopoietic Transplant and Cell Therapy

    Frontiers in immunology, Vol. 14, pp. 1165759

2022

  1. CT-275 Incidence and Characteristics of Chronic GVHD in Haploidentical Stem-Cell Transplantation With Post-Transplantation Cyclophosfamide: Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC)

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S440-S441

2021

  1. Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers

    Transplantation and Cellular Therapy, Vol. 27, Núm. 6, pp. 493.e1-493.e8

  2. Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study

    Bone Marrow Transplantation, Vol. 56, Núm. 8, pp. 1919-1928

  3. Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group

    Transplant Infectious Disease, Vol. 23, Núm. 4

  4. Clinical outcomes of allogeneic hematopoietic stem cell transplant recipients developing Cytomegalovirus DNAemia prior to engraftment

    Bone Marrow Transplantation, Vol. 56, Núm. 6, pp. 1281-1290

  5. Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: Analysis from the Spanish Hematopoietic Transplantation and Cell Therapy Group

    American Journal of Transplantation, Vol. 21, Núm. 1, pp. 258-271

  6. Seasonal Human Coronavirus Respiratory Tract Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

    The Journal of infectious diseases, Vol. 223, Núm. 9, pp. 1564-1575

2019

  1. Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH)

    European Journal of Haematology, Vol. 102, Núm. 6, pp. 465-471

2017

  1. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

2015

  1. A registry-based study of non-Aspergillus mould infections in recipients of allogeneic haematopoietic cell transplantation

    Clinical Microbiology and Infection

  2. Outcome of graft failure after allogeneic stem cell transplant: Study of 89 patients

    Leukemia and Lymphoma, Vol. 56, Núm. 3, pp. 656-662

  3. Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: A randomized controlled trial

    Clinical Infectious Diseases, Vol. 60, Núm. 3, pp. 405-414

  4. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia

    Blood Cancer Journal, Vol. 5, pp. e352

  5. The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature

    Oncotarget, Vol. 6, Núm. 31, pp. 31613-31627

2014

  1. MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia

    Leukemia